|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
R, Torre L and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Groot PM, Wu CC, Carter BW and Munden
RF: The epidemiology of lung cancer. Transl Lung Cancer Res.
7:220–233. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zeng X, Liu D, Peng G, Liu J and Yang H:
MiroRNA-31-3p promotes the invasion and metastasis of
non-small-cell lung cancer cells by targeting forkhead box 1
(FOXO1). Comput Math Methods Med. 2022:45970872022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alexander M, Kim SY and Cheng H: Update
2020: Management of Non-small cell lung cancer. Lung. 198:897–907.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sadreddini S, Baradaran B, Aghebati-Maleki
A, Sadreddini S, Shanehbandi D, Fotouhi A and Aghebati-Maleki L:
Immune checkpoint blockade opens a new way to cancer immunotherapy.
J Cell Physiol. 234:8541–8549. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sperandio RC, Pestana RC, Miyamura BV and
Kaseb AO: Hepato-cellular carcinoma immunotherapy. Annu Rev Med.
73:267–278. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kjeldsen JW, Lorentzen CL, Martinenaite E,
Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed
SM, Weis-Banke SE, et al: A phase 1/2 trial of an immune-modulatory
vaccine against IDO/PD-L1 in combination with nivolumab in
metastatic melanoma. Nat Med. 27:2212–2223. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Masuda K, Horinouchi H, Tanaka M,
Higashiyama R, Shinno Y, Sato J, Matsumoto Y, Okuma Y, Yoshida T,
Goto Y, et al: Efficacy of anti-PD-1 antibodies in NSCLC patients
with an EGFR mutation and high PD-L1 expression. J Cancer Res Clin
Oncol. 147:245–251. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhatia A and Burtness B: Treating head and
neck cancer in the age of immunotherapy: A 2023 update. Drugs.
83:217–248. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meyers DE, Bryan PM, Banerji S and Morris
DG: Targeting the PD-1/PD-L1 axis for the treatment of
non-small-cell lung cancer. Curr Oncol. 25:e324–e334. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Negrao MV, Skoulidis F, Montesion M,
Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, et al:
Oncogene-specific differences in tumor mutational burden, PD-L1
expression, and outcomes from immunotherapy in non-small cell lung
cancer. J Immunother Cancer. 9:e0028912021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yokosuka T, Takamatsu M,
Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M and Saito T:
Programmed cell death 1 forms negative costimulatory microclusters
that directly inhibit T cell receptor signaling by recruiting
phosphatase SHP2. J Exp Med. 209:1201–1217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Topalian SL, Drake CG and Pardoll DM:
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor
immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mu CY, Huang JA, Chen Y, Chen C and Zhang
XG: High expression of PD-L1 in lung cancer may contribute to poor
prognosis and tumor cells immune escape through suppressing tumor
infiltrating dendritic cells maturation. Med Oncol. 28:682–688.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rashed HE, Abdelrahman AE, Abdelgawad M,
Balata S and Shabrawy ME: Prognostic significance of programmed
cell death ligand 1 (PD-L1), CD8+ tumor-infiltrating lymphocytes
and p53 in non-small cell lung cancer: An immunohistochemical
study. Turk Patoloji Derg. 1:211–222. 2017.PubMed/NCBI
|
|
17
|
Lamberti G, Sisi M, Andrini E, Palladini
A, Giunchi F, Lollini PL, Ardizzoni A and Gelsomino F: The
mechanisms of PD-L1 regulation in non-small-cell lung cancer
(NSCLC): Which are the involved players? Cancers (Basel).
12:31292020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang J, Jia Y, Wang B, Yang S, Du K, Luo
Y, Li Y and Zhu B: Circular RNA CHST15 sponges miR-155-5p and
miR-194-5p to promote the immune escape of lung cancer cells
mediated by PD-L1. Front Oncol. 11:5956092021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lei J, Zhu J, Hui B, Jia C, Yan X, Jiang T
and Wang X: Circ-HSP90A expedites cell growth, stemness, and immune
evasion in non-small cell lung cancer by regulating STAT3 signaling
and PD-1/PD-L1 checkpoint. Cancer Immunol Immunother. 72:101–124.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu F, Cheng C, Qin H, Wang H and Yu H: A
novel circular RNA circENTPD7 contributes to glioblastoma
progression by targeting ROS1. Cancer Cell Int. 20:1182020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu H, Zhang Y, Zhang L, Yang R, Liao Z and
Zhou T: Circular RNA circENTPD7 suppresses the accumulation of PTEN
to promote cell proliferation in non-small cell lung cancer. Genet
Mol Biol. 45:e202200232022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bong D, Sohn J and Lee SV: Brief guide to
RT-qPCR. Mol Cells. 47:1001412024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang X, Wang J, Deng X, Xiong F, Ge J,
Xiang B, Wu X, Ma J, Zhou M, Li X, et al: Role of the tumor
microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol
Cancer. 18:102019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jing H, Meng M, Ye M, Liu S, Cao X, Li K,
Liu Y, Zhang J and Wu Y: Integrin α2 promotes immune escape in
non-small-cell lung cancer by enhancing PD-L1 expression in
exosomes to inhibit CD8 + T-cell activity. J Investig Med.
72:57–66. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Attieh F, Chartouni A, Boutros M, Mouawad
A and Kourie HR: Tackling the immunotherapy conundrum: Advances and
challenges for operable non-small-cell lung cancer treatment.
Immunotherapy. 15:1415–1428. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jancewicz I, Szarkowska J, Konopinski R,
Stachowiak M, Swiatek M, Blachnio K, Kubala S, Oksinska P, Cwiek P,
Rusetska N, et al: PD-L1 overexpression, SWI/SNF complex
deregulation, and profound transcriptomic changes characterize
cancer-dependent exhaustion of persistently activated
CD4+ T cells. Cancers (Basel). 13:41482021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang X and Liu J: Targeting PD-L1
(Programmed death-ligand 1) and inhibiting the expression of
IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2)
affect the proliferation and apoptosis of hypopharyngeal carcinoma
cells. Bioengineered. 12:7755–7764. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Q, Xiao M, Shi Y, Hu J, Bi T, Wang C,
Yan L and Li X: eIF5B regulates the expression of PD-L1 in prostate
cancer cells by interacting with Wig1. BMC Cancer. 21:10222021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Chen L and Qiang P: The role of
IGF2BP2, an m6A reader gene, in human metabolic diseases and
cancers. Cancer Cell Int. 21:992021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu X, Yu Y, Zong K, Lv P and Gu Y:
Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic
cancer promotes cancer proliferation by activating the PI3K/Akt
signaling pathway. J Exp Clin Cancer Res. 38:4972019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cui J, Tian J, Wang W, He T, Li X, Gu C,
Wang L, Wu J and Shang A: IGF2BP2 promotes the progression of
colorectal cancer through a YAP-dependent mechanism. Cancer Sci.
112:4087–4099. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guan H, Tian K, Luo W and Li M:
m6A-modified circRNA MYO1C participates in the tumor
immune surveillance of pancreatic ductal adenocarcinoma through
m6A/PD-L1 manner. Cell Death Dis. 14:1202023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang RS, Zheng YL, Li C, Ding C, Xu C and
Zhao J: MicroRNA-485-5p suppresses growth and metastasis in
non-small cell lung cancer cells by targeting IGF2BP2. Life Sci.
199:104–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Han L, Lei G, Chen Z, Zhang Y, Huang C and
Chen W: IGF2BP2 regulates MALAT1 by serving as an
N6-methyladenosine reader to promote NSCLC proliferation. Front Mol
Biosci. 8:7800892022. View Article : Google Scholar : PubMed/NCBI
|
